Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, Providence, RI, USA.
Equal3 Fertility, Cupertino, CA, USA.
Womens Health (Lond). 2022 Jan-Dec;18:17455065221074886. doi: 10.1177/17455065221074886.
Review the safety of fertility preservation through ovarian stimulation with oocyte or embryo cryopreservation, including cycle and medication options.
A systematic review of peer-reviewed sources revealed 2 applicable randomized control trials and 60 cohort studies as well as 20 additional expert opinions or reviews.
The capacity for future family building is important for the majority of reproductive age people, despite life-altering medical or oncologic diagnosis. Modern fertility preservation generates a high rate of oocyte yield while utilizing protocols that can be started at multiple points in the menstrual cycle and suppressing supra-physiologic levels of estrogen. Finally, more than one quarter of fertility preservation patients will return to later utilize fertility services.
For most patients, fertility preservation can safely be pursued and completed within 2 weeks without affecting disease severity or long-term survival.
回顾通过卵母细胞或胚胎冷冻保存进行卵巢刺激以保留生育能力的安全性，包括周期和药物选择。
对同行评议来源的系统评价显示，有 2 项适用的随机对照试验和 60 项队列研究，以及 20 项额外的专家意见或评论。
对于大多数处于生育年龄的人来说，未来的家庭建设能力很重要，尽管他们可能会面临改变生活的医学或肿瘤学诊断。现代生育力保存技术通过在月经周期的多个时间点开始并抑制超生理水平的雌激素的方案，产生了很高的卵母细胞产量。最后，超过四分之一的生育力保存患者将在以后返回使用生育力服务。
对于大多数患者而言，可以在 2 周内安全地进行生育力保存，而不会影响疾病的严重程度或长期生存。
